Overview

Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To demonstrate that tipranavir (TPV) co-administered with ritonavir (RTV) does not affect the QT interval more than placebo co-administered with ritonavir

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ritonavir
Tipranavir